title: Circulating TGF-β1, glycation, and oxidation in children with diabetes mellitus type 1.
abstract: The present study investigates the relationship between diabetes metabolic control represented by levels of HbA1c, early glycation products-(fructosamine (FAM)), serum-advanced glycation end products (s-AGEs), lipoperoxidation products (LPO), advanced oxidation protein products (AOPP) and circulating TGF-β in young patients with DM1. The study group consisted of 79 patients with DM1 (8-18 years). 31 healthy children were used as control (1-16 years). Baseline characteristics of patients were compared by Student's t-test and nonparametric Mann-Whitney test (Statdirect), respectively. The correlations between the measured parameters were examined using Pearson correlation coefficient r and Spearman's rank test, respectively. A P value < 0.05 was considered as statistically significant. HbA1c was measured by LPLC, s-AGEs spectrofluorimetrically, LPO and AOPP spectrophotometrically and TGF-β by ELISA. Our results showed that parameters of glycation and oxidation are significantly higher in patients with DM1 than in healthy control. The level of serum TGF-β was significantly higher in diabetics in comparison with control: 7.1(3.6; 12.6) versus 1.6(0.8; 3.9) ng/mL. TGF-β significantly correlated with age and duration of DM1. There was not found any significant relation between TGF-β and parameres of glycation and oxidation. However, these results do not exclude the association between TGF-β and the onset of diabetic complications.
authors.affiliation: Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Sasinkova 2, Bratislava 81108, Slovakia. vladimir.jakus@fmed.uniba.sk
authors.forename: Vladimír
authors.initials: V
authors.lastname: Jakuš
authors.forename: Michal
authors.initials: M
authors.lastname: Sapák
authors.forename: Jana
authors.initials: J
authors.lastname: Kostolanská
mesh_terms: D000293:Adolescent; D041923:Adolescent Development; D002648:Child; D002657:Child Development; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000378:metabolism* / Q000628:therapy; D019270:Fructosamine / Q000097:blood; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced / Q000097:blood*; D006031:Glycosylation; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007003:Hypoglycemia / Q000517:prevention & control; D050356:Lipid Metabolism; D015227:Lipid Peroxidation; D008054:Lipid Peroxides / Q000097:blood*; D008297:Male; D010084:Oxidation-Reduction; D053773:Transforming Growth Factor beta1 / Q000097:blood*; D015854:Up-Regulation
chemical_list: D019270:Fructosamine; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D008054:Lipid Peroxides; D053773:Transforming Growth Factor beta1; C508960:TGFB1 protein, human; C517652:hemoglobin A1c protein, human